Exploring neoadjuvant chemotherapy in a rare case of male breast cancer-a TEC-regimen (docetaxel, epirubicin, and cyclophosphamide) treatment: a case report and literature review.

AME Case Rep · 2026 · PMC13264720 · PMID 42299391

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A Swedish retrospective cohort study demonstrated that the proportion of male patients receiving NAC was comparable to that of female patients, but the rate of pathological complete response (pCR) in men, although lower, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.